nodes	percent_of_prediction	percent_of_DWPC	metapath
Nelarabine—Nucleic Acid Synthesis Inhibitors—Cytarabine—lymphatic system cancer	0.315	1	CiPCiCtD
Nelarabine—Fludarabine—lymphatic system cancer	0.142	0.514	CrCtD
Nelarabine—Cytarabine—lymphatic system cancer	0.134	0.486	CrCtD
Nelarabine—POLA1—Fludarabine—lymphatic system cancer	0.0706	0.368	CbGbCtD
Nelarabine—POLA1—Cytarabine—lymphatic system cancer	0.0481	0.251	CbGbCtD
Nelarabine—DCK—Fludarabine—lymphatic system cancer	0.0434	0.227	CbGbCtD
Nelarabine—DCK—Cytarabine—lymphatic system cancer	0.0296	0.155	CbGbCtD
Nelarabine—Adenosine triphosphate—Fludarabine—lymphatic system cancer	0.0116	0.062	CrCrCtD
Nelarabine—Ribavirin—Fludarabine—lymphatic system cancer	0.0108	0.0575	CrCrCtD
Nelarabine—Ribavirin—Cytarabine—lymphatic system cancer	0.0102	0.0543	CrCrCtD
Nelarabine—S-Adenosylmethionine—Fludarabine—lymphatic system cancer	0.01	0.0536	CrCrCtD
Nelarabine—Clofarabine—Fludarabine—lymphatic system cancer	0.01	0.0536	CrCrCtD
Nelarabine—Regadenoson—Fludarabine—lymphatic system cancer	0.01	0.0536	CrCrCtD
Nelarabine—Regadenoson—Cytarabine—lymphatic system cancer	0.00947	0.0506	CrCrCtD
Nelarabine—S-Adenosylmethionine—Cytarabine—lymphatic system cancer	0.00947	0.0506	CrCrCtD
Nelarabine—Clofarabine—Cytarabine—lymphatic system cancer	0.00947	0.0506	CrCrCtD
Nelarabine—Fludarabine—Cytarabine—lymphatic system cancer	0.00889	0.0475	CrCrCtD
Nelarabine—Adenosine monophosphate—Fludarabine—lymphatic system cancer	0.00887	0.0474	CrCrCtD
Nelarabine—Cytarabine—Fludarabine—lymphatic system cancer	0.00839	0.0448	CrCrCtD
Nelarabine—Adenosine monophosphate—Cytarabine—lymphatic system cancer	0.00837	0.0448	CrCrCtD
Nelarabine—Azacitidine—Fludarabine—lymphatic system cancer	0.00797	0.0426	CrCrCtD
Nelarabine—Cladribine—Fludarabine—lymphatic system cancer	0.00797	0.0426	CrCrCtD
Nelarabine—Adenosine—Fludarabine—lymphatic system cancer	0.00797	0.0426	CrCrCtD
Nelarabine—Vidarabine—Fludarabine—lymphatic system cancer	0.00797	0.0426	CrCrCtD
Nelarabine—Azacitidine—Cytarabine—lymphatic system cancer	0.00753	0.0402	CrCrCtD
Nelarabine—Vidarabine—Cytarabine—lymphatic system cancer	0.00753	0.0402	CrCrCtD
Nelarabine—Adenosine—Cytarabine—lymphatic system cancer	0.00753	0.0402	CrCrCtD
Nelarabine—Decitabine—Cytarabine—lymphatic system cancer	0.00717	0.0383	CrCrCtD
Nelarabine—POLA1—Vinblastine—Vincristine—lymphatic system cancer	0.000536	1	CbGdCrCtD
Nelarabine—Adenosine triphosphate—ALK—lymphatic system cancer	0.00052	1	CrCbGaD
Nelarabine—Diarrhoea—Mechlorethamine—lymphatic system cancer	5.93e-05	0.00207	CcSEcCtD
Nelarabine—Neutropenia—Carmustine—lymphatic system cancer	5.91e-05	0.00206	CcSEcCtD
Nelarabine—Myalgia—Fludarabine—lymphatic system cancer	5.86e-05	0.00205	CcSEcCtD
Nelarabine—Arthralgia—Fludarabine—lymphatic system cancer	5.86e-05	0.00205	CcSEcCtD
Nelarabine—Hypoaesthesia—Bleomycin—lymphatic system cancer	5.77e-05	0.00201	CcSEcCtD
Nelarabine—Hyperglycaemia—Carmustine—lymphatic system cancer	5.7e-05	0.00199	CcSEcCtD
Nelarabine—Dyspnoea—Teniposide—lymphatic system cancer	5.7e-05	0.00199	CcSEcCtD
Nelarabine—Petechiae—Methotrexate—lymphatic system cancer	5.67e-05	0.00198	CcSEcCtD
Nelarabine—Pneumonia—Carmustine—lymphatic system cancer	5.67e-05	0.00198	CcSEcCtD
Nelarabine—Confusional state—Fludarabine—lymphatic system cancer	5.66e-05	0.00198	CcSEcCtD
Nelarabine—Neutropenia—Vincristine—lymphatic system cancer	5.64e-05	0.00197	CcSEcCtD
Nelarabine—Depression—Carmustine—lymphatic system cancer	5.62e-05	0.00196	CcSEcCtD
Nelarabine—Oedema—Fludarabine—lymphatic system cancer	5.61e-05	0.00196	CcSEcCtD
Nelarabine—Infection—Fludarabine—lymphatic system cancer	5.58e-05	0.00195	CcSEcCtD
Nelarabine—Decreased appetite—Teniposide—lymphatic system cancer	5.55e-05	0.00194	CcSEcCtD
Nelarabine—Neuropathy peripheral—Carmustine—lymphatic system cancer	5.52e-05	0.00193	CcSEcCtD
Nelarabine—Vomiting—Mechlorethamine—lymphatic system cancer	5.51e-05	0.00192	CcSEcCtD
Nelarabine—Nervous system disorder—Fludarabine—lymphatic system cancer	5.51e-05	0.00192	CcSEcCtD
Nelarabine—Thrombocytopenia—Fludarabine—lymphatic system cancer	5.5e-05	0.00192	CcSEcCtD
Nelarabine—Neutropenia—Mitoxantrone—lymphatic system cancer	5.49e-05	0.00192	CcSEcCtD
Nelarabine—Stomatitis—Carmustine—lymphatic system cancer	5.49e-05	0.00192	CcSEcCtD
Nelarabine—Speech disorder—Methotrexate—lymphatic system cancer	5.42e-05	0.0019	CcSEcCtD
Nelarabine—Pneumonia—Vincristine—lymphatic system cancer	5.41e-05	0.00189	CcSEcCtD
Nelarabine—Depression—Vincristine—lymphatic system cancer	5.36e-05	0.00187	CcSEcCtD
Nelarabine—Anorexia—Fludarabine—lymphatic system cancer	5.35e-05	0.00187	CcSEcCtD
Nelarabine—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	5.3e-05	0.00185	CcSEcCtD
Nelarabine—Neuropathy peripheral—Vincristine—lymphatic system cancer	5.27e-05	0.00184	CcSEcCtD
Nelarabine—Pneumonia—Mitoxantrone—lymphatic system cancer	5.27e-05	0.00184	CcSEcCtD
Nelarabine—Feeling abnormal—Teniposide—lymphatic system cancer	5.26e-05	0.00184	CcSEcCtD
Nelarabine—Stomatitis—Vincristine—lymphatic system cancer	5.24e-05	0.00183	CcSEcCtD
Nelarabine—Gastrointestinal pain—Teniposide—lymphatic system cancer	5.22e-05	0.00183	CcSEcCtD
Nelarabine—Chills—Bleomycin—lymphatic system cancer	5.2e-05	0.00182	CcSEcCtD
Nelarabine—Nausea—Mechlorethamine—lymphatic system cancer	5.15e-05	0.0018	CcSEcCtD
Nelarabine—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	5.13e-05	0.00179	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	5.12e-05	0.00179	CcSEcCtD
Nelarabine—Stomatitis—Mitoxantrone—lymphatic system cancer	5.11e-05	0.00178	CcSEcCtD
Nelarabine—Abdominal pain—Teniposide—lymphatic system cancer	5.05e-05	0.00176	CcSEcCtD
Nelarabine—Body temperature increased—Teniposide—lymphatic system cancer	5.05e-05	0.00176	CcSEcCtD
Nelarabine—Paraesthesia—Fludarabine—lymphatic system cancer	5.04e-05	0.00176	CcSEcCtD
Nelarabine—Hypoaesthesia—Carmustine—lymphatic system cancer	5.03e-05	0.00176	CcSEcCtD
Nelarabine—Hyperuricaemia—Methotrexate—lymphatic system cancer	5.03e-05	0.00176	CcSEcCtD
Nelarabine—Dyspnoea—Fludarabine—lymphatic system cancer	5.01e-05	0.00175	CcSEcCtD
Nelarabine—Oedema peripheral—Carmustine—lymphatic system cancer	4.98e-05	0.00174	CcSEcCtD
Nelarabine—Connective tissue disorder—Carmustine—lymphatic system cancer	4.97e-05	0.00174	CcSEcCtD
Nelarabine—Dysarthria—Methotrexate—lymphatic system cancer	4.93e-05	0.00172	CcSEcCtD
Nelarabine—Sinusitis—Mitoxantrone—lymphatic system cancer	4.91e-05	0.00172	CcSEcCtD
Nelarabine—Decreased appetite—Fludarabine—lymphatic system cancer	4.88e-05	0.00171	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	4.85e-05	0.00169	CcSEcCtD
Nelarabine—Fatigue—Fludarabine—lymphatic system cancer	4.84e-05	0.00169	CcSEcCtD
Nelarabine—Hypoaesthesia—Vincristine—lymphatic system cancer	4.8e-05	0.00168	CcSEcCtD
Nelarabine—Constipation—Fludarabine—lymphatic system cancer	4.8e-05	0.00168	CcSEcCtD
Nelarabine—Pain—Fludarabine—lymphatic system cancer	4.8e-05	0.00168	CcSEcCtD
Nelarabine—Urinary tract disorder—Vincristine—lymphatic system cancer	4.77e-05	0.00167	CcSEcCtD
Nelarabine—Blood uric acid increased—Methotrexate—lymphatic system cancer	4.75e-05	0.00166	CcSEcCtD
Nelarabine—Connective tissue disorder—Vincristine—lymphatic system cancer	4.74e-05	0.00166	CcSEcCtD
Nelarabine—Urethral disorder—Vincristine—lymphatic system cancer	4.73e-05	0.00165	CcSEcCtD
Nelarabine—Eye disorder—Carmustine—lymphatic system cancer	4.73e-05	0.00165	CcSEcCtD
Nelarabine—Anaemia—Bleomycin—lymphatic system cancer	4.66e-05	0.00163	CcSEcCtD
Nelarabine—Feeling abnormal—Fludarabine—lymphatic system cancer	4.63e-05	0.00162	CcSEcCtD
Nelarabine—Asthenia—Teniposide—lymphatic system cancer	4.58e-05	0.0016	CcSEcCtD
Nelarabine—Leukopenia—Bleomycin—lymphatic system cancer	4.52e-05	0.00158	CcSEcCtD
Nelarabine—Depressed level of consciousness—Methotrexate—lymphatic system cancer	4.5e-05	0.00157	CcSEcCtD
Nelarabine—Cardiac disorder—Vincristine—lymphatic system cancer	4.48e-05	0.00157	CcSEcCtD
Nelarabine—Body temperature increased—Fludarabine—lymphatic system cancer	4.44e-05	0.00155	CcSEcCtD
Nelarabine—Mental disorder—Carmustine—lymphatic system cancer	4.43e-05	0.00155	CcSEcCtD
Nelarabine—Malnutrition—Carmustine—lymphatic system cancer	4.4e-05	0.00154	CcSEcCtD
Nelarabine—Cough—Bleomycin—lymphatic system cancer	4.4e-05	0.00154	CcSEcCtD
Nelarabine—Angiopathy—Vincristine—lymphatic system cancer	4.38e-05	0.00153	CcSEcCtD
Nelarabine—Diarrhoea—Teniposide—lymphatic system cancer	4.37e-05	0.00153	CcSEcCtD
Nelarabine—Mediastinal disorder—Vincristine—lymphatic system cancer	4.35e-05	0.00152	CcSEcCtD
Nelarabine—Chest pain—Bleomycin—lymphatic system cancer	4.29e-05	0.0015	CcSEcCtD
Nelarabine—Myalgia—Bleomycin—lymphatic system cancer	4.29e-05	0.0015	CcSEcCtD
Nelarabine—Coma—Methotrexate—lymphatic system cancer	4.26e-05	0.00149	CcSEcCtD
Nelarabine—Back pain—Carmustine—lymphatic system cancer	4.26e-05	0.00149	CcSEcCtD
Nelarabine—Mental disorder—Vincristine—lymphatic system cancer	4.23e-05	0.00148	CcSEcCtD
Nelarabine—Chills—Mitoxantrone—lymphatic system cancer	4.22e-05	0.00147	CcSEcCtD
Nelarabine—Neoplasm—Methotrexate—lymphatic system cancer	4.22e-05	0.00147	CcSEcCtD
Nelarabine—Confusional state—Bleomycin—lymphatic system cancer	4.15e-05	0.00145	CcSEcCtD
Nelarabine—Vision blurred—Carmustine—lymphatic system cancer	4.15e-05	0.00145	CcSEcCtD
Nelarabine—Tremor—Carmustine—lymphatic system cancer	4.13e-05	0.00144	CcSEcCtD
Nelarabine—Oedema—Bleomycin—lymphatic system cancer	4.12e-05	0.00144	CcSEcCtD
Nelarabine—Infection—Bleomycin—lymphatic system cancer	4.09e-05	0.00143	CcSEcCtD
Nelarabine—Anaemia—Carmustine—lymphatic system cancer	4.07e-05	0.00142	CcSEcCtD
Nelarabine—Back pain—Vincristine—lymphatic system cancer	4.07e-05	0.00142	CcSEcCtD
Nelarabine—Vomiting—Teniposide—lymphatic system cancer	4.06e-05	0.00142	CcSEcCtD
Nelarabine—Sepsis—Methotrexate—lymphatic system cancer	4.05e-05	0.00141	CcSEcCtD
Nelarabine—Thrombocytopenia—Bleomycin—lymphatic system cancer	4.03e-05	0.00141	CcSEcCtD
Nelarabine—Asthenia—Fludarabine—lymphatic system cancer	4.03e-05	0.00141	CcSEcCtD
Nelarabine—Dysgeusia—Mitoxantrone—lymphatic system cancer	4.01e-05	0.0014	CcSEcCtD
Nelarabine—Headache—Teniposide—lymphatic system cancer	4e-05	0.0014	CcSEcCtD
Nelarabine—Back pain—Mitoxantrone—lymphatic system cancer	3.96e-05	0.00138	CcSEcCtD
Nelarabine—Leukopenia—Carmustine—lymphatic system cancer	3.94e-05	0.00138	CcSEcCtD
Nelarabine—Anorexia—Bleomycin—lymphatic system cancer	3.92e-05	0.00137	CcSEcCtD
Nelarabine—Anaemia—Vincristine—lymphatic system cancer	3.88e-05	0.00136	CcSEcCtD
Nelarabine—Vision blurred—Mitoxantrone—lymphatic system cancer	3.86e-05	0.00135	CcSEcCtD
Nelarabine—Hypotension—Bleomycin—lymphatic system cancer	3.85e-05	0.00134	CcSEcCtD
Nelarabine—Diarrhoea—Fludarabine—lymphatic system cancer	3.84e-05	0.00134	CcSEcCtD
Nelarabine—Convulsion—Carmustine—lymphatic system cancer	3.81e-05	0.00133	CcSEcCtD
Nelarabine—Nausea—Teniposide—lymphatic system cancer	3.79e-05	0.00133	CcSEcCtD
Nelarabine—Anaemia—Mitoxantrone—lymphatic system cancer	3.78e-05	0.00132	CcSEcCtD
Nelarabine—Leukopenia—Vincristine—lymphatic system cancer	3.76e-05	0.00131	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	3.75e-05	0.00131	CcSEcCtD
Nelarabine—Chest pain—Carmustine—lymphatic system cancer	3.75e-05	0.00131	CcSEcCtD
Nelarabine—Myalgia—Carmustine—lymphatic system cancer	3.75e-05	0.00131	CcSEcCtD
Nelarabine—Paraesthesia—Bleomycin—lymphatic system cancer	3.7e-05	0.00129	CcSEcCtD
Nelarabine—Dyspnoea—Bleomycin—lymphatic system cancer	3.67e-05	0.00128	CcSEcCtD
Nelarabine—Leukopenia—Mitoxantrone—lymphatic system cancer	3.66e-05	0.00128	CcSEcCtD
Nelarabine—Convulsion—Vincristine—lymphatic system cancer	3.64e-05	0.00127	CcSEcCtD
Nelarabine—Confusional state—Carmustine—lymphatic system cancer	3.62e-05	0.00127	CcSEcCtD
Nelarabine—Oedema—Carmustine—lymphatic system cancer	3.59e-05	0.00126	CcSEcCtD
Nelarabine—Decreased appetite—Bleomycin—lymphatic system cancer	3.58e-05	0.00125	CcSEcCtD
Nelarabine—Myalgia—Vincristine—lymphatic system cancer	3.58e-05	0.00125	CcSEcCtD
Nelarabine—Cough—Mitoxantrone—lymphatic system cancer	3.57e-05	0.00125	CcSEcCtD
Nelarabine—Infection—Carmustine—lymphatic system cancer	3.57e-05	0.00125	CcSEcCtD
Nelarabine—Vomiting—Fludarabine—lymphatic system cancer	3.57e-05	0.00125	CcSEcCtD
Nelarabine—Convulsion—Mitoxantrone—lymphatic system cancer	3.55e-05	0.00124	CcSEcCtD
Nelarabine—Pain—Bleomycin—lymphatic system cancer	3.52e-05	0.00123	CcSEcCtD
Nelarabine—Thrombocytopenia—Carmustine—lymphatic system cancer	3.52e-05	0.00123	CcSEcCtD
Nelarabine—Headache—Fludarabine—lymphatic system cancer	3.52e-05	0.00123	CcSEcCtD
Nelarabine—Arthralgia—Mitoxantrone—lymphatic system cancer	3.48e-05	0.00122	CcSEcCtD
Nelarabine—Myalgia—Mitoxantrone—lymphatic system cancer	3.48e-05	0.00122	CcSEcCtD
Nelarabine—Chest pain—Mitoxantrone—lymphatic system cancer	3.48e-05	0.00122	CcSEcCtD
Nelarabine—Lethargy—Methotrexate—lymphatic system cancer	3.46e-05	0.00121	CcSEcCtD
Nelarabine—Oedema—Vincristine—lymphatic system cancer	3.43e-05	0.0012	CcSEcCtD
Nelarabine—Anorexia—Carmustine—lymphatic system cancer	3.43e-05	0.0012	CcSEcCtD
Nelarabine—Infection—Vincristine—lymphatic system cancer	3.41e-05	0.00119	CcSEcCtD
Nelarabine—Feeling abnormal—Bleomycin—lymphatic system cancer	3.39e-05	0.00119	CcSEcCtD
Nelarabine—Osteoarthritis—Methotrexate—lymphatic system cancer	3.39e-05	0.00118	CcSEcCtD
Nelarabine—Confusional state—Mitoxantrone—lymphatic system cancer	3.37e-05	0.00118	CcSEcCtD
Nelarabine—Nervous system disorder—Vincristine—lymphatic system cancer	3.36e-05	0.00118	CcSEcCtD
Nelarabine—Thrombocytopenia—Vincristine—lymphatic system cancer	3.36e-05	0.00117	CcSEcCtD
Nelarabine—Hypotension—Carmustine—lymphatic system cancer	3.36e-05	0.00117	CcSEcCtD
Nelarabine—Oedema—Mitoxantrone—lymphatic system cancer	3.34e-05	0.00117	CcSEcCtD
Nelarabine—Nausea—Fludarabine—lymphatic system cancer	3.33e-05	0.00117	CcSEcCtD
Nelarabine—Infection—Mitoxantrone—lymphatic system cancer	3.32e-05	0.00116	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	3.27e-05	0.00114	CcSEcCtD
Nelarabine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	3.27e-05	0.00114	CcSEcCtD
Nelarabine—Anorexia—Vincristine—lymphatic system cancer	3.27e-05	0.00114	CcSEcCtD
Nelarabine—Body temperature increased—Bleomycin—lymphatic system cancer	3.25e-05	0.00114	CcSEcCtD
Nelarabine—Insomnia—Carmustine—lymphatic system cancer	3.25e-05	0.00114	CcSEcCtD
Nelarabine—Paraesthesia—Carmustine—lymphatic system cancer	3.23e-05	0.00113	CcSEcCtD
Nelarabine—Hypotension—Vincristine—lymphatic system cancer	3.21e-05	0.00112	CcSEcCtD
Nelarabine—Dyspnoea—Carmustine—lymphatic system cancer	3.2e-05	0.00112	CcSEcCtD
Nelarabine—Somnolence—Carmustine—lymphatic system cancer	3.19e-05	0.00112	CcSEcCtD
Nelarabine—Anorexia—Mitoxantrone—lymphatic system cancer	3.18e-05	0.00111	CcSEcCtD
Nelarabine—Ataxia—Methotrexate—lymphatic system cancer	3.18e-05	0.00111	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	3.13e-05	0.00109	CcSEcCtD
Nelarabine—Decreased appetite—Carmustine—lymphatic system cancer	3.12e-05	0.00109	CcSEcCtD
Nelarabine—Hypotension—Mitoxantrone—lymphatic system cancer	3.12e-05	0.00109	CcSEcCtD
Nelarabine—Insomnia—Vincristine—lymphatic system cancer	3.1e-05	0.00108	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	3.1e-05	0.00108	CcSEcCtD
Nelarabine—Paraesthesia—Vincristine—lymphatic system cancer	3.08e-05	0.00108	CcSEcCtD
Nelarabine—Pain—Carmustine—lymphatic system cancer	3.07e-05	0.00107	CcSEcCtD
Nelarabine—Constipation—Carmustine—lymphatic system cancer	3.07e-05	0.00107	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	3.04e-05	0.00106	CcSEcCtD
Nelarabine—Paraesthesia—Mitoxantrone—lymphatic system cancer	3e-05	0.00105	CcSEcCtD
Nelarabine—Decreased appetite—Vincristine—lymphatic system cancer	2.98e-05	0.00104	CcSEcCtD
Nelarabine—Dyspnoea—Mitoxantrone—lymphatic system cancer	2.98e-05	0.00104	CcSEcCtD
Nelarabine—Somnolence—Mitoxantrone—lymphatic system cancer	2.97e-05	0.00104	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	2.96e-05	0.00103	CcSEcCtD
Nelarabine—Feeling abnormal—Carmustine—lymphatic system cancer	2.96e-05	0.00103	CcSEcCtD
Nelarabine—Fatigue—Vincristine—lymphatic system cancer	2.96e-05	0.00103	CcSEcCtD
Nelarabine—Asthenia—Bleomycin—lymphatic system cancer	2.95e-05	0.00103	CcSEcCtD
Nelarabine—Gastrointestinal pain—Carmustine—lymphatic system cancer	2.94e-05	0.00103	CcSEcCtD
Nelarabine—Constipation—Vincristine—lymphatic system cancer	2.93e-05	0.00102	CcSEcCtD
Nelarabine—Pain—Vincristine—lymphatic system cancer	2.93e-05	0.00102	CcSEcCtD
Nelarabine—Decreased appetite—Mitoxantrone—lymphatic system cancer	2.9e-05	0.00101	CcSEcCtD
Nelarabine—Fatigue—Mitoxantrone—lymphatic system cancer	2.88e-05	0.00101	CcSEcCtD
Nelarabine—Pain—Mitoxantrone—lymphatic system cancer	2.86e-05	0.000998	CcSEcCtD
Nelarabine—Constipation—Mitoxantrone—lymphatic system cancer	2.86e-05	0.000998	CcSEcCtD
Nelarabine—Abdominal pain—Carmustine—lymphatic system cancer	2.84e-05	0.000992	CcSEcCtD
Nelarabine—Body temperature increased—Carmustine—lymphatic system cancer	2.84e-05	0.000992	CcSEcCtD
Nelarabine—Gastrointestinal pain—Vincristine—lymphatic system cancer	2.8e-05	0.00098	CcSEcCtD
Nelarabine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	2.75e-05	0.000962	CcSEcCtD
Nelarabine—Neutropenia—Methotrexate—lymphatic system cancer	2.74e-05	0.000956	CcSEcCtD
Nelarabine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	2.73e-05	0.000954	CcSEcCtD
Nelarabine—Body temperature increased—Vincristine—lymphatic system cancer	2.71e-05	0.000947	CcSEcCtD
Nelarabine—Abdominal pain—Vincristine—lymphatic system cancer	2.71e-05	0.000947	CcSEcCtD
Nelarabine—Body temperature increased—Mitoxantrone—lymphatic system cancer	2.64e-05	0.000923	CcSEcCtD
Nelarabine—Abdominal pain—Mitoxantrone—lymphatic system cancer	2.64e-05	0.000923	CcSEcCtD
Nelarabine—Pneumonia—Methotrexate—lymphatic system cancer	2.62e-05	0.000917	CcSEcCtD
Nelarabine—Vomiting—Bleomycin—lymphatic system cancer	2.62e-05	0.000914	CcSEcCtD
Nelarabine—Infestation NOS—Methotrexate—lymphatic system cancer	2.61e-05	0.000912	CcSEcCtD
Nelarabine—Infestation—Methotrexate—lymphatic system cancer	2.61e-05	0.000912	CcSEcCtD
Nelarabine—Depression—Methotrexate—lymphatic system cancer	2.6e-05	0.000909	CcSEcCtD
Nelarabine—Asthenia—Carmustine—lymphatic system cancer	2.58e-05	0.000901	CcSEcCtD
Nelarabine—Stomatitis—Methotrexate—lymphatic system cancer	2.54e-05	0.000889	CcSEcCtD
Nelarabine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	2.47e-05	0.000862	CcSEcCtD
Nelarabine—Epistaxis—Methotrexate—lymphatic system cancer	2.46e-05	0.00086	CcSEcCtD
Nelarabine—Asthenia—Vincristine—lymphatic system cancer	2.46e-05	0.00086	CcSEcCtD
Nelarabine—Diarrhoea—Carmustine—lymphatic system cancer	2.46e-05	0.000859	CcSEcCtD
Nelarabine—Nausea—Bleomycin—lymphatic system cancer	2.45e-05	0.000854	CcSEcCtD
Nelarabine—Asthenia—Mitoxantrone—lymphatic system cancer	2.4e-05	0.000837	CcSEcCtD
Nelarabine—Dizziness—Carmustine—lymphatic system cancer	2.38e-05	0.00083	CcSEcCtD
Nelarabine—Diarrhoea—Vincristine—lymphatic system cancer	2.35e-05	0.00082	CcSEcCtD
Nelarabine—Urinary tract disorder—Methotrexate—lymphatic system cancer	2.31e-05	0.000808	CcSEcCtD
Nelarabine—Urethral disorder—Methotrexate—lymphatic system cancer	2.3e-05	0.000802	CcSEcCtD
Nelarabine—Diarrhoea—Mitoxantrone—lymphatic system cancer	2.29e-05	0.000799	CcSEcCtD
Nelarabine—Vomiting—Carmustine—lymphatic system cancer	2.28e-05	0.000798	CcSEcCtD
Nelarabine—Dizziness—Vincristine—lymphatic system cancer	2.27e-05	0.000793	CcSEcCtD
Nelarabine—Headache—Carmustine—lymphatic system cancer	2.25e-05	0.000787	CcSEcCtD
Nelarabine—Eye disorder—Methotrexate—lymphatic system cancer	2.19e-05	0.000765	CcSEcCtD
Nelarabine—Vomiting—Vincristine—lymphatic system cancer	2.18e-05	0.000762	CcSEcCtD
Nelarabine—Cardiac disorder—Methotrexate—lymphatic system cancer	2.17e-05	0.00076	CcSEcCtD
Nelarabine—Headache—Vincristine—lymphatic system cancer	2.15e-05	0.000751	CcSEcCtD
Nelarabine—Nausea—Carmustine—lymphatic system cancer	2.13e-05	0.000746	CcSEcCtD
Nelarabine—Angiopathy—Methotrexate—lymphatic system cancer	2.13e-05	0.000743	CcSEcCtD
Nelarabine—Vomiting—Mitoxantrone—lymphatic system cancer	2.12e-05	0.000742	CcSEcCtD
Nelarabine—Mediastinal disorder—Methotrexate—lymphatic system cancer	2.11e-05	0.000738	CcSEcCtD
Nelarabine—Chills—Methotrexate—lymphatic system cancer	2.1e-05	0.000734	CcSEcCtD
Nelarabine—Headache—Mitoxantrone—lymphatic system cancer	2.09e-05	0.000731	CcSEcCtD
Nelarabine—Mental disorder—Methotrexate—lymphatic system cancer	2.05e-05	0.000717	CcSEcCtD
Nelarabine—Malnutrition—Methotrexate—lymphatic system cancer	2.04e-05	0.000713	CcSEcCtD
Nelarabine—Nausea—Vincristine—lymphatic system cancer	2.04e-05	0.000712	CcSEcCtD
Nelarabine—Dysgeusia—Methotrexate—lymphatic system cancer	2e-05	0.000698	CcSEcCtD
Nelarabine—Nausea—Mitoxantrone—lymphatic system cancer	1.98e-05	0.000693	CcSEcCtD
Nelarabine—Back pain—Methotrexate—lymphatic system cancer	1.97e-05	0.000689	CcSEcCtD
Nelarabine—Vision blurred—Methotrexate—lymphatic system cancer	1.92e-05	0.000672	CcSEcCtD
Nelarabine—Anaemia—Methotrexate—lymphatic system cancer	1.88e-05	0.000659	CcSEcCtD
Nelarabine—Leukopenia—Methotrexate—lymphatic system cancer	1.83e-05	0.000638	CcSEcCtD
Nelarabine—Cough—Methotrexate—lymphatic system cancer	1.78e-05	0.000622	CcSEcCtD
Nelarabine—Convulsion—Methotrexate—lymphatic system cancer	1.77e-05	0.000617	CcSEcCtD
Nelarabine—Chest pain—Methotrexate—lymphatic system cancer	1.74e-05	0.000607	CcSEcCtD
Nelarabine—Myalgia—Methotrexate—lymphatic system cancer	1.74e-05	0.000607	CcSEcCtD
Nelarabine—Arthralgia—Methotrexate—lymphatic system cancer	1.74e-05	0.000607	CcSEcCtD
Nelarabine—Confusional state—Methotrexate—lymphatic system cancer	1.68e-05	0.000586	CcSEcCtD
Nelarabine—Infection—Methotrexate—lymphatic system cancer	1.65e-05	0.000578	CcSEcCtD
Nelarabine—Nervous system disorder—Methotrexate—lymphatic system cancer	1.63e-05	0.00057	CcSEcCtD
Nelarabine—Thrombocytopenia—Methotrexate—lymphatic system cancer	1.63e-05	0.000569	CcSEcCtD
Nelarabine—Anorexia—Methotrexate—lymphatic system cancer	1.59e-05	0.000554	CcSEcCtD
Nelarabine—Hypotension—Methotrexate—lymphatic system cancer	1.56e-05	0.000543	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	1.52e-05	0.00053	CcSEcCtD
Nelarabine—Insomnia—Methotrexate—lymphatic system cancer	1.51e-05	0.000526	CcSEcCtD
Nelarabine—Paraesthesia—Methotrexate—lymphatic system cancer	1.49e-05	0.000522	CcSEcCtD
Nelarabine—Dyspnoea—Methotrexate—lymphatic system cancer	1.48e-05	0.000518	CcSEcCtD
Nelarabine—Somnolence—Methotrexate—lymphatic system cancer	1.48e-05	0.000517	CcSEcCtD
Nelarabine—Decreased appetite—Methotrexate—lymphatic system cancer	1.45e-05	0.000506	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	1.44e-05	0.000502	CcSEcCtD
Nelarabine—Fatigue—Methotrexate—lymphatic system cancer	1.43e-05	0.000501	CcSEcCtD
Nelarabine—Pain—Methotrexate—lymphatic system cancer	1.42e-05	0.000497	CcSEcCtD
Nelarabine—Feeling abnormal—Methotrexate—lymphatic system cancer	1.37e-05	0.000479	CcSEcCtD
Nelarabine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	1.36e-05	0.000476	CcSEcCtD
Nelarabine—Abdominal pain—Methotrexate—lymphatic system cancer	1.32e-05	0.00046	CcSEcCtD
Nelarabine—Body temperature increased—Methotrexate—lymphatic system cancer	1.32e-05	0.00046	CcSEcCtD
Nelarabine—Asthenia—Methotrexate—lymphatic system cancer	1.19e-05	0.000417	CcSEcCtD
Nelarabine—Diarrhoea—Methotrexate—lymphatic system cancer	1.14e-05	0.000398	CcSEcCtD
Nelarabine—Dizziness—Methotrexate—lymphatic system cancer	1.1e-05	0.000385	CcSEcCtD
Nelarabine—Vomiting—Methotrexate—lymphatic system cancer	1.06e-05	0.00037	CcSEcCtD
Nelarabine—Headache—Methotrexate—lymphatic system cancer	1.04e-05	0.000364	CcSEcCtD
Nelarabine—Nausea—Methotrexate—lymphatic system cancer	9.89e-06	0.000345	CcSEcCtD
